Nextgen Biomed Ltd (TLV:NXGN)
54.00
-0.90 (-1.64%)
May 14, 2025, 10:56 AM IDT
Nextgen Biomed Balance Sheet
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 0.02 | 0.05 | 5.24 | 11.96 | 5.67 | Upgrade
|
Short-Term Investments | 0.02 | 0.02 | - | - | 0.02 | Upgrade
|
Cash & Short-Term Investments | 0.04 | 0.07 | 5.24 | 11.96 | 5.69 | Upgrade
|
Cash Growth | -46.15% | -98.76% | -56.19% | 110.08% | 199.63% | Upgrade
|
Other Receivables | 0.1 | 0.07 | - | 0.15 | 0.16 | Upgrade
|
Receivables | 0.1 | 0.07 | - | 0.15 | 0.16 | Upgrade
|
Prepaid Expenses | 0.06 | 0.01 | 0.01 | 0.16 | 0.05 | Upgrade
|
Restricted Cash | 0.03 | 0.08 | - | - | - | Upgrade
|
Total Current Assets | 0.23 | 0.23 | 5.25 | 12.27 | 5.9 | Upgrade
|
Property, Plant & Equipment | 0.31 | 0.03 | - | 0.01 | 0.01 | Upgrade
|
Other Intangible Assets | - | - | 1.55 | 7.29 | - | Upgrade
|
Other Long-Term Assets | 0.03 | - | - | - | 0.5 | Upgrade
|
Total Assets | 0.58 | 0.26 | 14.89 | 23.63 | 8.32 | Upgrade
|
Accounts Payable | 0.18 | 0.15 | 0.17 | 0.14 | 0.07 | Upgrade
|
Accrued Expenses | 2.5 | 1.02 | 1.09 | 0.73 | 0.63 | Upgrade
|
Current Portion of Leases | 0.11 | - | - | - | - | Upgrade
|
Other Current Liabilities | 0.14 | 0.07 | - | - | 0.75 | Upgrade
|
Total Current Liabilities | 2.92 | 1.24 | 1.26 | 0.87 | 1.45 | Upgrade
|
Long-Term Leases | 0.12 | - | - | - | - | Upgrade
|
Other Long-Term Liabilities | - | - | 1.38 | 2.14 | - | Upgrade
|
Total Liabilities | 3.04 | 1.24 | 2.64 | 3.01 | 1.45 | Upgrade
|
Additional Paid-In Capital | 67.08 | 64.4 | 63.43 | 57.96 | 38.2 | Upgrade
|
Retained Earnings | -70.94 | -66.05 | -51.86 | -43.29 | -40.74 | Upgrade
|
Treasury Stock | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | Upgrade
|
Comprehensive Income & Other | 1.53 | 0.8 | 0.8 | 6.07 | 9.52 | Upgrade
|
Total Common Equity | -2.34 | -0.86 | 12.36 | 20.72 | 6.97 | Upgrade
|
Minority Interest | -0.12 | -0.12 | -0.11 | -0.1 | -0.1 | Upgrade
|
Shareholders' Equity | -2.47 | -0.98 | 12.25 | 20.62 | 6.87 | Upgrade
|
Total Liabilities & Equity | 0.58 | 0.26 | 14.89 | 23.63 | 8.32 | Upgrade
|
Total Debt | 0.22 | - | - | - | - | Upgrade
|
Net Cash (Debt) | -0.19 | 0.07 | 5.24 | 11.96 | 5.69 | Upgrade
|
Net Cash Growth | - | -98.76% | -56.19% | 110.08% | 199.63% | Upgrade
|
Net Cash Per Share | -0.02 | 0.01 | 0.73 | 1.80 | 1.05 | Upgrade
|
Filing Date Shares Outstanding | 10.9 | 7.29 | 7.22 | 7.22 | 6.34 | Upgrade
|
Total Common Shares Outstanding | 10.9 | 7.29 | 7.22 | 7.22 | 5.53 | Upgrade
|
Working Capital | -2.7 | -1.01 | 3.99 | 11.4 | 4.45 | Upgrade
|
Book Value Per Share | -0.21 | -0.12 | 1.71 | 2.87 | 1.26 | Upgrade
|
Tangible Book Value | -2.34 | -0.86 | 10.81 | 13.43 | 6.97 | Upgrade
|
Tangible Book Value Per Share | -0.21 | -0.12 | 1.50 | 1.86 | 1.26 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.